Short Interest in PURE Bioscience (OTCMKTS:PURE) Declines By 65.0%

PURE Bioscience (OTCMKTS:PURE) was the target of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 3,865 shares, a decrease of 65.0% from the June 30th total of 11,031 shares. Based on an average daily volume of 68,596 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are short sold.

PURE Bioscience Price Performance

Shares of OTCMKTS PURE traded down $0.01 during midday trading on Monday, reaching $0.07. 377 shares of the stock traded hands, compared to its average volume of 32,201. PURE Bioscience has a one year low of $0.04 and a one year high of $0.14. The company’s 50 day moving average is $0.07 and its 200 day moving average is $0.06. The stock has a market capitalization of $8.70 million, a PE ratio of -2.23 and a beta of 0.22.

PURE Bioscience (OTCMKTS:PURE) last issued its quarterly earnings data on Monday, June 15th. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $0.51 million during the quarter.

About PURE Bioscience

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.